FDA Approves Roivant's LISRAYA (Brepocitinib) for Adult Dermatomyositis
On August 27, 2026, Roivant announced that the U.S. Food and Drug Administration approved LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis. Roivant’s release described LISRAYA as the first and only targeted therapy approved for dermatomyositis and stated that it could be prescribed in the United States immediately.
The atomic, forward-looking development is the FDA approval of LISRAYA (brepocitinib) for adult dermatomyositis; the separate mosliciguat and IMVT-1402 data are excluded. The supporting press-release context identifies August 27, 2026 as the approval announcement date and states that the treatment was available for prescription in the United States immediately. The original September 10 timestamp reflects the summary publication rather than the real-world event, so the occurrence date is corrected to August 27 with the time set to 00:00 UTC as a placeholder because no exact approval time is provided. The approval is highly material to Roivant because it creates a commercial launch for the first and only targeted dermatomyositis therapy, although its single-company scope limits breadth. Surprise is set to moderate because the evidence does not state market expectations or whether approval was ahead of schedule. Only ROIV is approved as a stakeholder because the other listed companies have indirect, conditional, or insufficiently specific exposure to this approval.
Significant clinical and financial progress was highlighted, including FDA approval for brepocitinib, best-in-class data for mosliciguat in PH-ILD, and strong efficacy for IMVT-1402 in RA.